GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CV Sciences Inc (OTCPK:CVSI) » Definitions » Debt-to-Equity

CV Sciences (CV Sciences) Debt-to-Equity : 0.12 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is CV Sciences Debt-to-Equity?

CV Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.25 Mil. CV Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.02 Mil. CV Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $2.36 Mil. CV Sciences's debt to equity for the quarter that ended in Mar. 2024 was 0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CV Sciences's Debt-to-Equity or its related term are showing as below:

CVSI' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.97   Med: 0.15   Max: 1.31
Current: 0.12

During the past 13 years, the highest Debt-to-Equity Ratio of CV Sciences was 1.31. The lowest was -1.97. And the median was 0.15.

CVSI's Debt-to-Equity is ranked better than
68.88% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs CVSI: 0.12

CV Sciences Debt-to-Equity Historical Data

The historical data trend for CV Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CV Sciences Debt-to-Equity Chart

CV Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.69 0.26 -1.97 0.15

CV Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.07 0.06 0.15 0.12

Competitive Comparison of CV Sciences's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, CV Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CV Sciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CV Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CV Sciences's Debt-to-Equity falls into.



CV Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CV Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

CV Sciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CV Sciences  (OTCPK:CVSI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


CV Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CV Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


CV Sciences (CV Sciences) Business Description

Traded in Other Exchanges
Address
9530 Padgett Street, Suite 107, San Diego, CA, USA, 92126
CV Sciences Inc is a consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, which are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). The company also operates a drug development program focused on developing and commercializing cannabidiol (CBD)-based novel therapeutics.
Executives
William Mccorkle director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Corroon James Michael Jr. director 9530 PADGETT STREET, SUITE 107, SAN DIEGO CA 92126
Maroon Joseph C Md director 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mona Michael Joseph Jr director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Paul Blake director 145 BRANDYWINE PKWY, WEST CHESTER PA 19380
Douglas Jesse Mackay officer: Sr VP Scientific/Regulatory 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Joseph D Dowling officer: Chief Financial Officer 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Joerg Grasser officer: CFO 2688 SOUTH RAINBOW BLVD STE B, LAS VEGAS NV 89146
Elizabeth Ann Altman director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Terri F Graham director C/O JACK IN THE BOX INC, 9330 BALVOA AVE, SAN DIEGO CA 92123
Stephen Martin Schmitz director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Gary Sligar director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
James A Mcnulty director C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Larry Phillip Raskin director 1630 FUNNY CIDE DRIVE, WAXHAW NC 28173
Mackay Ventures Inc. other: Member 10% holding group 6325 S. JONES BOULEVARD #500, LAS VEGAS NV 89118